In this picture from April 13, 2023, bottles of Mifepristone pills are shown at a family planning facility, in Rockville, Md.Anna Moneymaker/Getty Images, FILE
The nation’s highest court on Thursday maintained widespread access to the abortion medication mifepristone without requiring an in-person visit to a physician, thus keeping suspended a decision from a lower court which would have limited the medication’s accessibility as legal proceedings regarding FDA safety guidelines unfold.
The upshot is that patients can still get a prescription for the drug through telehealth and either pick it up from a pharmacy or have it shipped to them. According to the ACLU, more than a quarter of women opting for abortion today receive the medication via telehealth.
Justices Clarence Thomas and Samuel Alito expressed their dissent regarding the ruling.
In this picture from April 13, 2023, bottles of Mifepristone pills are shown at a family planning facility, in Rockville, Md.Anna Moneymaker/Getty Images, FILE
The court did not go into detail regarding its verdict, however, the action parallels the tactic it used two years prior in a comparable instance launched by a coalition of anti-abortion medical professionals.
Back in 2021, the FDA eliminated the requirement for in-person dispensing of the drug, referencing data from 15 investigations encompassing in excess of 55,000 patients that the agency stated demonstrated that eased access was safe.
Louisiana, which initiated the case, claims that government regulators behaved in an arbitrary fashion, neglecting to properly consider possible health detriments.
The state had appealed to the justices to uphold – even if only temporarily – a ruling from the court of appeals, which determined that the Biden administration didn’t legitimately create the new guidelines for mifepristone and that they ought to be suspended.
Drugmakers Danco Labs and GenBioPro, supported by 20 states, maintain that the FDA thoroughly examined the guidelines and that they have been safely put into practice over the preceding five years with very few grievances or disputes.
They emphasized that no federal court has ever questioned FDA-approved drug rules.
"We are delighted that a safe and effective medication that Americans rely on will continue to be obtainable while this legal process carries on," Abby Long, a spokesperson for Danco, stated in a press release. "Danco is also sure that an assessment of all current, reliable data by the FDA will continue to verify that [mifepristone] is exceedingly safe and effective."
Louisiana Attorney General Liz Murrill communicated via statement, "It’s astonishing that the Supreme Court would hinder this logical return to medically ethical procedures and oversight. DOJ failed to defend Big Pharma, which is cashing in on the unlawful and immoral dissemination of abortion pills. We will keep up the fight."
Sourse: abcnews.go.com